You just read:

Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia

News provided by

Neurocrine Biosciences, Inc.

Mar 21, 2017, 08:59 ET